ArticleNature immunology2014
Vaccines that stimulate T cell immunity to HIV-1: the next step.
Article in Nature immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.The Journal of infectious diseases · 2016Trial
- Article
- Key Factors and Parameter Ranges for Immune Control of Equine Infectious Anemia Virus Infection.Viruses · 2023Article
- Molecular insights into antibody-mediated protection against the prototypic simian immunodeficiency virus.Nature communications · 2022Article
- Targeted Immuno-Antiretroviral to Promote Dual Protection against HIV: A Proof-of-Concept Study.Nanomaterials (Basel, Switzerland) · 2022Article
- A longitudinal analysis of immune escapes from HLA-B*13-restricted T-cell responses at early stage of CRF01_AE subtype HIV-1 infection and implications for vaccine design.BMC immunology · 2022Article
- Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Article
- Utilizing Computational Machine Learning Tools to Understand Immunogenic Breadth in the Context of a CD8 T-Cell Mediated HIV Response.Frontiers in immunology · 2021Article
- Review
- An SAMT-247 Microbicide Provides Potent Protection against Intravaginal Simian Immunodeficiency Virus Infection of Rhesus Macaques, whereas an Added Vaccine Component Elicits Mixed Outcomes.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers.Nature medicine · 2020Article
- High-Throughput Identification of MHC Class I Binding Peptides Using an Ultradense Peptide Array.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.ACS biomaterials science & engineering · 2020Review
- Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B.Vaccines · 2020Article
- Article
- Identification of Immunodominant HIV-1 Epitopes Presented by HLA-C*12:02, a Protective Allele, Using an Immunopeptidomics Approach.Journal of virology · 2019Article
- Protein and Glycan Mimicry in HIV Vaccine Design.Journal of molecular biology · 2019Review
- Structure-Based Vaccine Antigen Design.Annual review of medicine · 2019Review
- Impact of Endemic Infections on HIV Susceptibility in Sub-Saharan Africa.Tropical diseases, travel medicine and vaccines · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The search for a vaccine against human immunodeficiency virus type 1 (HIV-1) has many hurdles to overcome. Ideally, the stimulation of both broadly neutralizing antibodies and cell-mediated immune responses remains the best option, but no candidate in clinical trials at present has elicited such antibodies, and efficacy trials have not demonstrated any benefit for vaccines designed to stimulate immune responses of CD8(+) T cells. Findings obtained with the simian immunodeficiency virus (SIV) monkey model have provided new evidence that stimulating effective CD8(+) T cell immunity could provide protection, and in this Perspective we explore the path forward for optimizing such responses in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.